comparemela.com

Latest Breaking News On - First in ventures - Page 5 : comparemela.com

Pluton Biosciences gets $6 6M in seed funding, Bayer AG soil deal and more : Biofuels Digest

Pluton Biosciences gets $6 6M in seed funding, Bayer AG soil deal and more : Biofuels Digest
biofuelsdigest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biofuelsdigest.com Daily Mail and Mail on Sunday newspapers.

Pluton Biosciences looks to nature for cutting edge biotech solutions, raising $6 6M seed – TechCrunch

Many of the problems we face today in biology and agriculture have been faced before but not by humans. Somewhere in nature there is a microscopic creature that accomplishes naturally and efficiently what chemists and bioengineers are struggling to do at all and Pluton Biosciences claims to have pioneered a way to find […]

Precision Oncology Company 4baseCare launches one-of-its-kind Indian Population Specific Cancer Gene Panel

Bangalore (Karnataka) [India], August 18 (ANI/NewsVoir): 4baseCare, a precision oncology company in India, launched their product - TARGT Indiegene, India's largest and first population-specific tumour gene panel derived from Whole Exome and Whole Transcriptome data of over 1,500 cancer patients across 28 different cancer types. Most of the patients were presented with stage III/IV disease, and presented with disease progression and had exhausted all the options in the standard of care.

Gliknik Raises $11 5M in Series C Financing

Gliknik Raises $11.5M in Series C Financing Gliknik Inc., a Baltimore, MD-based immunology company dedicated to patients with cancer and autoimmune disorders, completed an $11.5m Series C financing. The round was led by First In Ventures (FIV) with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. Kyle Rusconi, a founder of FIV, is joining the Gliknik Board. Led by CEO David Block, Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders. The company, which has secured $81m to date, intends to use the funds to progress the pipeline of its product candidates, including:

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.